// App-Quantinova.ai

e23237 : Use of next generation sequencing and quantitative mass spectrometry to determine HER2 status.

Researchers

Presenter

  • Pedram Razavi

Principal Investigators

  • Fabiola Cecchi

  • Dara S. Ross

  • Sumit Middha

  • Ahmet Zehir

  • Maria E. Arcila

  • Todd A. Hembrough

  • Michael F. Berger

  • Maurizio Scaltriti

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • NantOmics, LLC., Rockville, MD

  • NantOmics, LLC., Rockville, MD

Locations

  • United States

Companies

  • NantWorks, LLC

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved